Defining the Need for Prostate Cancer Radiotherapy in the General Population: A Criterion-based Benchmarking Approach

Clinical Oncology

Volumn 22, Issue 10, 2010, Pages 801-809

  Kerba, M ^a   Miao, Qun ^b   Zhang Salomons, J ^b   Mackillop, W ^b,c  

^a TOM BAKER CANCER CENTRE   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c Cancer Centre of Southeastern Ontario   (Canada)

Author keywords

Health services; Population outcomes; Prostate cancer; Prostatectomy; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANADA; CANCER CENTER; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; UNITED STATES;

AGED; AGED, 80 AND OVER; BENCHMARKING; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEER PROGRAM;

EID: 78149495579     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.07.006     Document Type: Article

References (59)

1. Board of the Faculty of Clinical Oncology Equipment, workload and staffing for radiotherapy in the UK 1997-2002 2003, The Royal College of Radiologists, London.
2. Denham J.W. How do we bring an acceptable level of radiotherapy services to a dispersed population?. Australas Radiol 1995, 39(2):171-173.
3. Mackillop W.J., Dixon P., Zhou Y., et al. Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol 1994, 32(2):106-115.
4. Mackillop W.J., Groome P.A., Zhang-Salomons J., et al. Does a centralized radiotherapy system provide adequate access to care?. J Clin Oncol 1997, 15(3):1261-1271.
5. Slotman B.J., Leer J.W. Infrastructure of radiotherapy in the Netherlands: evaluation of progress and introduction of a new model for determining needs. Radiother Oncol 2003, 66(3):345-349.
6. Barbera L., Zhang-Salomons J., Huang J., Tyldesley S., Mackillop W.J. Defining the need for radiotherapy for lung cancer in the general population. A criterion-based, benchmarking approach. Med Care 2003, 41(9):1074-1085.
7. Bentzen S.M., Heeren G., Cottier B., et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 2005, 75(3):355-365.
8. Frodin J.E., Jonsson E., Moller T., et al. Radiotherapy in Sweden: a study of present use in relation to the literature and an estimate of future trends. Acta Oncol 1996, 35(8):967-979.
9. Ontario Cancer Treatment and Research Foundation A plan for radiation treatment, province of Ontario, 1995-2000 1995, Ontario Cancer Treatment and Research Foundation, Toronto.
10. Delaney G., Jacob S., Barton M. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies. Cancer 2005, 103(3):462-473.
11. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005, 104(6):1129-1137.
12. Foroudi F., Tyldesley S., Barbera L., Huang J., Mackillop W.J. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys 2003, 55(1):51-63.
13. Foroudi F., Tyldesley S., Walker H., Mackillop W.J. An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol 2002, 53(5):1240-1253.
14. Foroudi F., Tyldesley S., Barbera L., Huang J., Mackillop W.J. An evidence-based estimate of the appropriate radiotherapy utilization rate for colorectal cancer. Int J Radiat Oncol Biol Phys 2003, 56(5):1295-1307.
15. Tyldesley S., Boyd C., Schulze K., et al. Estimating the need for radiotherapy for lung cancer: an evidence-based epidemiological approach. Int J Radiat Oncol Biol Phys 2001, 49(4):973-985.
16. Usmani N., Foroudi F., Du J., et al. An evidence-based estimate of the appropriate rate of utilization of radiotherapy for cancer of the cervix. Int J Radiat Oncol Biol Phys 2005, 63(3):812-827.
17. Bogan C.E., English M.J. Benchmarking for best practices: winning through innovative adaptation 1994, McGraw-Hill, New York. 1st ed.
18. Kerba M., Miao Q., Zhang-Salomons J., Mackillop W.J. Defining the need for breast cancer radiotherapy in the general population: a criterion-based benchmarking approach. Clin Oncol 2007, 19(7):481-489.
19. Mock U., Mayer R., Potter R., et al. The med AUSTRON/OGRO patterns of care study on radiotherapy indications in Austria. Radiother Oncol 2004, 73(Suppl. 2):S29-34.
20. Statistics Canada Demographic statistics Available at:, Accessed 26 January 2010. http://www.statcan.ca/Daily/English/050928/d050928a.htm.
21. Clarke E.A., Marrett L.D., Kreiger N. Cancer registration in Ontario: a computer approach. IARC Sci Publ 1991, 95:246-257.
22. Robles S.C., Marrett L.D., Clarke E.A., et al. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 1988, 41(5):495-501.
23. Cancer Care Ontario Cancer patients being treated closer to home Available at:, Accessed 26 January 2010. http://www.cancercare.on.ca/index_newsReleases2001.htm.
24. Surveillance, Epidemiology, and End Results (SEER) Program. SEER 1973-2002 Public-Use Data Available at:, Accessed 26 January 2010. http://seer.cancer.gov/publicdata.
25. Howe H.L. Cancer incidence in North America, 1988-1991 1995, North American Association of Central Cancer Registries, Sacramento, CA.
26. Nattinger A.B., McAuliffe T.L., Schapira M.M. Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 1997, 50(8):939-945.
27. World Health Organization International classification of disease, revised, vol. I. 1977, World Health Organization, Geneva.
28. Percy C., Van Holten C., Muir C. International classification for oncology (ICD-O) 1990, World Health Organization, Geneva. 2nd ed.
29. Fritz A., Ries L. The SEER program code manual 1998, National Institutes of Health, Bethesda, MD.
30. Zhang-Salomons J., Mackillop W.J. Estimating the lifetime utilization rate of radiotherapy in cancer patients: the Multicohort Current Utilization Table (MCUT) method. Comput Meth Programs Biomed 2008, 92(1):99-108.
31. Huang J., Zhou S., Groome P., et al. Factors affecting the use of palliative radiotherapy in Ontario. J Clin Oncol 2001, 19(1):137-144.
32. Armitage P., Berry G. Statistical methods in medical research 1994, Blackwell Scientific, Oxford. 3rd ed.
33. Evans R.G. Supplier-induced demand: some empirical evidence and implications. The economics of health and medical care 1974, 162-173. John Wiley & Sons, New York. M. Perlman (Ed.).
34. Hemenway D., Killen A., Cashman S.B., et al. Physicians' responses to financial incentives. Evidence from a for-profit ambulatory care center. N Engl J Med 1990, 322(15):1059-1063.
35. Krasnik A., Groenewegen P.P., Pedersen P.A., et al. Changing remuneration systems: effects on activity in general practice. Br Med J 1990, 300(6741):1698-1701.
36. Lievens Y., Van Den Bogaert W., Rijnders A., et al. Palliative radiotherapy practice within western European countries: impact of the radiotherapy financing system?. Radiother Oncol 2000, 56(3):289-295.
37. Mitchell J.M., Sunshine J.H. Consequences of physicians' ownership of health care facilities: joint ventures in radiation therapy. N Engl J Med 1992, 327(21):1497-1501.
38. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993, 270(8):948-954.
39. Jhaveri F.M., Klein E.A., Kupelian P.A., et al. Declining rates of extracapsular extension after radical prostatectomy: evidence of continued stage migration. J Clin Oncol 1999, 17(10):3167-3172.
40. Ohori M., Wheelet T.M., Dunn J.K., et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994, 152:1714-1720.
41. Soh S., Kattam M.W., Berkman S., et al. Has there been a recent shift in pathological features and prognosis of patients treated with radical prostatectomy?. J Urol 1997, 157(6):2212-2218.
42. Stamey T.A., Donaldson A.N., Yemoto C.E., et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiological significance of annual changes. J Urol 1998, 160(6 Pt 2):2412-2417.
43. Mazur D.J., Merz J.F. How older patients' treatment preferences are influenced about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. J Am Ger Soc 1996, 44(8):934-937.
44. Murray N., Coy P., Pater J.L., et al. Importance of timing of thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993, 11(2):336-344.
45. Ostelind K., Hansen H.H., Hansen H.S., et al. Chemotherapy versus chemotherapy plus radiotherapy in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br J Cancer 1986, 54(1):7-17.
46. Rothenbacher D., Lutz M.P., Porzsolt F. Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it. Eur J Cancer 1997, 33(8):1184-1189.
47. Tyldesley S., Zhang-Salomons J., Groome P.A., et al. Association between age and the utilization of radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 2000, 47(2):469-480.
48. Vulto A., Louwman M., Rodrigus P., Coebergh J.W. Referral rates and trends in radiotherapy as part of primary treatment of cancer in South Netherlands, 1988-2002. Radiother Oncol 2006, 78(2):131-137.
49. Aus G., Robinson D., Rosell J., et al. Survival in prostate carcinoma - outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based national prostate cancer registry of Sweden. Cancer 2005, 103(5):943-951.
50. Feldman-Stewart D., Brundage M.D., Nickel J.C., Mackillop W.J. The information required by patients with early-stage prostate cancer in choosing their treatment. BJU Int 2001, 87(3):218-223.
51. Mettlin C.J., Murphy G.P., Cunningham M.P., Menck H.R. The national cancer data base report on race, age, and region variations in prostate cancer treatment. Cancer 1997, 80(7):1261-1266.
52. Shavers V.L., Brown M.L., Potosky A.L., et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med 2004, 19(2):146-155.
53. Alibhai S.M., Krahn M.D., Cohen M.M., et al. Is there age bias in the treatment of localized prostate carcinoma?. Cancer 2004, 100(1):72-81.
54. Krahn M.D., Bremner K.E., Asaria J., et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology 2002, 60(2):258-263.
55. Mettlin C., Murphy G.P., Menck H. Trends in treatment of localized prostate cancer by radical prostatectomy: observations from the Commission on Cancer national cancer database, 1985-1990. Urology 1994, 43(4):488-492.
56. Moul J.W., Wu H., Sun L., et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 2002, 132(2):213-219.
57. Huang M, King W, Mackillop WJ. The influence of waiting times on treatment choices among prostate cancer patients [dissertation]. Kingston, Ontario: Queen's University, 2006.
58. Hillner B.E., McDonald M.K., Penberthy L., et al. Measuring standards of care for early breast cancer in an insured population. J Clin Oncol 1997, 15(4):1401-1408.
59. Richards M.A., Parrott J.C. Tertiary cancer services in Britain: benchmarking study of activity and facilities at 12 specialist centres. Br Med J 1996, 313(7053):347-349.